Famotidine’S Possible Cutaneous Rash in Covid-19 Patients: An Adverse Effect Case Series Publisher Pubmed



Salehi M¹ ; Khalili H² ; Jahani Z¹ ; Rasoolinejad M¹ ; Ghiasvanad F¹ Show Affiliations
Source: Current Drug Safety Published:2022

Abstract

Background: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, the side effects on skin of the medications used for COVID-19, such as famotidine, have not been studied. Objective: This case series aims to present challenges in defining cutaneous manifestations of famo-tidine in the context of COVID-19. Case Presentation: We identified patients from Imam Khomeini hospital complex who were admitted to the ward due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), were taking famotidine and having cutaneous rash. Clinical data were obtained through observation and intervention. Discussion: We found 4 SARS-CoV-2 patients with cutaneous manifestations. The mean (±SD) age of the patients was 57±2 years, 3 patients were men, and their COVID-19 symptoms appeared 10±3 days before admission. The most common symptoms were cough and shortness of breath. All the patients were admitted for hypoxemic respiratory failure. Patients received famotidine for gas-trointestinal prophylaxis, and all 4 patients developed Acral macular mountainous skin lesions in the upper and lower extremities, then we discontinued famotidine and lesions were recovered com-pletely in all patients. Conclusion: These cases prompted us to inform clinicians about cutaneous complications of famo-tidine in COVID-19 patients. © 2022 Bentham Science Publishers.